https://doi.org/10.55788/5ad29264
The SELECT trial (NCT03574597) is a randomised, double-blind, multicentre, phase 3 trial of semaglutide versus placebo which enrolled participants with BMI ≥27 kg/m2 and established cardiovascular disease but no diabetes to assess cardiovascular outcomes [1]. The current renal prespecified analysis, presented by Prof. Helen M. Colhoun (The University of Edinburgh, United Kingdom), used a 5-point composite endpoint defined as death due to kidney causes, initiation of chronic kidney replacement therapy (dialysis or transplant), onset of persistent eGFR <15 mL/min/1.73 m2, persistent eGFR reduction from baseline of ≥50%, or onset of persistent microalbuminuria. These analyses were performed on the entire cohort of SELECT (n=17604) [2].
The time-to-occurrence of the 5-component kidney endpoint was significantly longer with semaglutide compared with placebo. After a median follow-up of 182 weeks, 1.8% of participants receiving semaglutide and 2.2% receiving placebo achieved the composite endpoint (HR 0.78; 95% CI 0.63–0.96; P=0.02). When analysing the individual components of the composite endpoint, the efficacy results were mainly driven by improvement in time-to-onset of eGFR reduction from baseline of ≥50% (HR 0.57; 95% CI 0.27–1.14; P=0.11) and time-to-onset of microalbuminuria (HR 0.80; 95% CI 0.64–1.00; P=0.05). No kidney-related deaths were observed for either group. Semaglutide further led to a treatment benefit of 0.75 mL/min/1.73 m2 (95% CI 0.43–0.96; P<0.001) in eGFR and -10.7% (95%CI -13.2 to -8.2; P<0.001) in urinary albumin-creatinine ratio at week 104, compared with placebo.
“In the absence of diabetes, 2.4 mg of semaglutide weekly reduced the composite kidney endpoint by 22% and had beneficial effects on eGFR and urine albumin-creatinine ratio”, summarised Prof. Colhoun. “These data add to the growing body of evidence on the potential kidney benefit of semaglutide”.
- Lincoff AM, et al. N Engl J Med. 2023;389(24):2221–2232.
- Colhoun HM, et al. Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial. Abstract #2496, ERA 2024, 23–26 May, Stockholm, Sweden.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results Next Article
The REACT score predicts relapse in ANCA-associated vasculitis »
« Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results Next Article
The REACT score predicts relapse in ANCA-associated vasculitis »
Table of Contents: ERA 2024
Featured articles
Meet the Experts: Navigating Kidneys and Genes
Chronic Kidney Disease
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes
The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials
Kidney Transplantation and Dialysis
CD38 inhibition by felzartamab promising for resolution of antibody-mediated rejection following kidney allografts
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen
KIR-HLA class I mismatch could be involved in antibody-mediated rejection of transplanted kidneys
IgA Nephropathy
Atrasentan shows positive interim results in IgA nephropathy: ALIGN phase 3 trial
Zigakibart slows down eGFR decline in IgA nephropathy
Long-term atacicept shows continued benefit in IgA nephropathy
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy
Cardio-Renal Interplay
Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes
Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results
MERCURI-1: Perioperative empagliflozin shows renal protection following cardiac surgery
Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes
Other Nephrology
Preview of the new KDIGO Guidelines for ADPKD, available later in 2024
APPEAR-C3G: Iptacopan shows promise for complement 3 glomerulopathy
Anti-nephrin autoantibody positivity describes a unique subclass of podocytopathies
Active vitamin D plus low-dose prednisolone is an alternative to high-dose prednisolone in minimal change disease
Claudin-1 is a potential antibody target for crescent glomerulonephritis
Rituximab protocol based on PLA2R1 epitope spreading outperforms the standard GEMRITUX protocol in membranous nephropathy
The REACT score predicts relapse in ANCA-associated vasculitis
Related Articles
November 28, 2023
Obinutuzumab attenuates kidney decline in lupus nephritis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com